trending Market Intelligence /marketintelligence/en/news-insights/trending/-SbL2b_F7rc8DoAK58mb_g2 content esgSubNav
In This List

Galectin Therapeutics closes private placements

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Galectin Therapeutics closes private placements

Galectin Therapeutics Inc. raised $3 million in a private placement of its common stock.

The company separately closed on an additional sale of its series B-3 preferred stock, resulting in about $1 million of additional proceeds.

In the placement of common stock, one existing investor and a new investor purchased 2,814,230 common shares and received warrants for common stock exercisable at $5.00 per share.

Under a Sept. 22 stock purchase agreement, 10X Fund LP purchased 1,008,000 series B-3 preferred shares, which are convertible into 896,997 common shares, for a purchase price of about $1 million. The fund also received warrants for common stock exercisable at $3.00 per share.

Peter Traber, president, CEO and chief medical officer, said in a statement that proceeds from the private placement will provide funding for the company's clinical programs, particularly a clinical trial that will assess the efficacy of Galectin's lead compound GR-MD-02 in patients with NASH cirrhosis, liver inflammation and damage caused by a buildup of fat in the liver.